"Great Potential To...": Adar Poonawalla's Tweet On 1st Batch Of Covovax

The jab is more than 90 per cent effective, the American vaccine maker said earlier this month, after a US study.

The Serum Institute of India, which is producing Novavax's COVID-19 vaccine in the country under the name Covovax, today said "a new milestone has been reached" as it began manufacturing the first batch of the vaccine this week at its Pune unit. Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia! pic.twitter.com/K4YzY6o73A The jab is more than 90 per cent effective, the American vaccine maker said earlier this month, after a US study. Adar Poonawalla, the CEO Of SII, this afternoon tweeted: "Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia! (sic)." The Serum Institute of India is the world's largest vaccine maker. India is yet to give an approval to a coronavirus vaccine for children. So far, three vaccines - Bharat Biotech's Covaxin, the SII's Covishield and Sputnik V - have been cleared for adults. Sources have said the SII plans to start Covovax trials for children next month.